Literature DB >> 18589357

Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma.

Vincent Wai-To Lam1, Kelvin Kwok-Chai Ng, Kenneth Siu-Ho Chok, Tan-To Cheung, Jimmy Yuen, Helen Tung, Wai-Kuen Tso, Sheung-Tat Fan, Ronnie T P Poon.   

Abstract

BACKGROUND: Local recurrence rates after radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC) vary from 2% to 36% in the literature. Limited data were available about the prognostic significance of local recurrence. STUDY
DESIGN: Between April 2001 and March 2006, 273 patients with 357 hepatocellular carcinoma nodules underwent RFA, with radiologically complete tumor ablation after a single session of RFA. The risk factors of local recurrence and its impact on overall survival of patients were analyzed.
RESULTS: With a median followup period of 24 months, local recurrence occurred in 35 patients (12.8%). By multivariate analysis, tumor size > 2.5 cm was the only independent risk factor for local recurrence. There was no notable difference in overall survival between patients with and without local recurrence. By multivariate analysis, local recurrence more than 12 months after RFA and complete response after additional treatment of local recurrence were associated with better overall survival in patients with local recurrence.
CONCLUSIONS: This study demonstrated that tumor size > 2.5 cm was the main risk factor for local recurrence after RFA of hepatocellular carcinoma. Our data suggested that additional aggressive treatment of local recurrence aimed at complete tumor response improves overall survival of patients. Late local recurrence was also associated with better prognosis, suggesting different tumor biology between early and late local recurrent tumors after RFA.

Entities:  

Mesh:

Year:  2008        PMID: 18589357     DOI: 10.1016/j.jamcollsurg.2008.01.020

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  57 in total

1.  A prognostic model and treatment strategy for intrahepatic recurrence of hepatocellular carcinoma after curative resection.

Authors:  Yuzo Umeda; Hiroaki Matsuda; Hiroshi Sadamori; Hiroyoshi Matsukawa; Takahito Yagi; Toshiyoshi Fujiwara
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

2.  Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma.

Authors:  M Sherman; K Burak; J Maroun; P Metrakos; J J Knox; R P Myers; M Guindi; G Porter; J R Kachura; P Rasuli; S Gill; P Ghali; P Chaudhury; J Siddiqui; D Valenti; A Weiss; R Wong
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

Review 3.  Local recurrence of hepatocellular carcinoma after radiofrequency ablation.

Authors:  Wang-Jun Liao; Min Shi; Jin-Zhang Chen; Ai-Min Li
Journal:  World J Gastroenterol       Date:  2010-10-28       Impact factor: 5.742

4.  Recurrence rates and factors for recurrence after radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma: a retrospective cohort study.

Authors:  Jeong Han Kim; Hyung Joon Yim; Kwang Gyun Lee; Seung Young Kim; Eun Suk Jung; Young Kul Jung; Ji Hoon Kim; Yeon Seok Seo; Jong Eun Yeon; Hong Sik Lee; Soon Ho Um; Kwan Soo Byun; Ho Sang Ryu
Journal:  Hepatol Int       Date:  2011-07-05       Impact factor: 6.047

5.  Laparoscopic microwave ablation in patients with hepatocellular carcinoma: a prospective cohort study.

Authors:  Umberto Cillo; Giulia Noaro; Alessandro Vitale; Daniele Neri; Francesco D'Amico; Enrico Gringeri; Fabio Farinati; Valter Vincenzi; Mario Vigo; Giacomo Zanus
Journal:  HPB (Oxford)       Date:  2014-04-18       Impact factor: 3.647

6.  Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma.

Authors:  Hirokazu Miyatake; Yoshiyuki Kobayashi; Yoshiaki Iwasaki; Shin-Ichiro Nakamura; Hideki Ohnishi; Kenji Kuwaki; Junichi Toshimori; Hiroaki Hagihara; Kazuhiro Nouso; Kazuhide Yamamoto
Journal:  Dig Dis Sci       Date:  2011-10-12       Impact factor: 3.199

7.  Stress-induced phosphoprotein 1 mediates hepatocellular carcinoma metastasis after insufficient radiofrequency ablation.

Authors:  Tianhong Su; Junbin Liao; Zihao Dai; Lixia Xu; Shuling Chen; Yifei Wang; Zhenwei Peng; Qiuyang Zhang; Sui Peng; Ming Kuang
Journal:  Oncogene       Date:  2018-03-21       Impact factor: 9.867

8.  Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment.

Authors:  Wei Yang; Kun Yan; S Nahum Goldberg; Muneeb Ahmed; Jung-Chieh Lee; Wei Wu; Zhong-Yi Zhang; Song Wang; Min-Hua Chen
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

9.  Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.

Authors:  Michael Vouche; Laura Kulik; Rohi Atassi; Khairuddin Memon; Ryan Hickey; Daniel Ganger; Frank H Miller; Vahid Yaghmai; Michael Abecassis; Talia Baker; Mary Mulcahy; Ritu Nayar; Robert J Lewandowski; Riad Salem
Journal:  Hepatology       Date:  2013-10-01       Impact factor: 17.425

10.  Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters.

Authors:  Ke Hao; John M Luk; Nikki P Y Lee; Mao Mao; Chunsheng Zhang; Mark D Ferguson; John Lamb; Hongyue Dai; Irene O Ng; Pak C Sham; Ronnie T P Poon
Journal:  BMC Cancer       Date:  2009-11-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.